<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-24930" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Malignant Melanoma Metastatic to the Central Nervous System</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lekkala</surname>
            <given-names>Manidhar Reddy</given-names>
          </name>
          <aff>University of Rochester Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mullangi</surname>
            <given-names>Sanjana</given-names>
          </name>
          <aff>Hillcrest Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manidhar Reddy Lekkala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sanjana Mullangi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>9</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-24930.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Malignant melanoma metastatic to the central nervous system is an important cause of morbidity and mortality. The management of these patients is rapidly evolving. This activity reviews the evaluation and management of malignant melanoma metastatic to the central nervous system, and reviews the role of the interprofessional team in evaluating and managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the etiology of malignant melanoma metastatic to the central nervous system.</p></list-item><list-item><p>Describe the evaluation of patients with malignant melanoma metastatic to the central nervous system.</p></list-item><list-item><p>Review the management considerations for patients with malignant melanoma metastatic to the central nervous system.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24930&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24930">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-24930.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Malignant melanoma is a serious form of skin cancer. It arises from the melanocytes which in turn originate from neural crest cells. The overall survival at 5 years depends on the extent and stage of the disease at diagnosis. Patients with advanced-stage melanoma are more likely to develop metastasis.<xref ref-type="bibr" rid="article-24930.r1">[1]</xref>&#x000a0;This topic will discuss the distant metastatic disease of malignant melanoma involving the central nervous system (CNS).</p>
      </sec>
      <sec id="article-24930.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Multiple etiologies were proposed for melanoma. The common etiologies are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ultraviolet radiation</p>
          </list-item>
          <list-item>
            <p>Indoor tanning</p>
          </list-item>
          <list-item>
            <p>PUVA therapy&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Light skin pigmentation, poor tanning ability</p>
          </list-item>
          <list-item>
            <p>FAMM syndrome and atypical mole syndrome</p>
          </list-item>
          <list-item>
            <p>Personal history of melanoma</p>
          </list-item>
          <list-item>
            <p>Familial history of melanoma</p>
          </list-item>
          <list-item>
            <p>Immunosuppressed patients with HIV, lymphoma, transplant history</p>
          </list-item>
          <list-item>
            <p>Drugs: TNF inhibitors, BRAF inhibitors</p>
          </list-item>
        </list>
        <p>Risk factors for CNS metastasis in Melanoma:</p>
        <list list-type="bullet">
          <list-item>
            <p>Male gender and age &#x0003e; 60 years<xref ref-type="bibr" rid="article-24930.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Deep invasive or ulcerated primary lesions<xref ref-type="bibr" rid="article-24930.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Acral, lentiginous, or nodular histology</p>
          </list-item>
          <list-item>
            <p>Involvement of &#x0003e;3 lymph nodes<xref ref-type="bibr" rid="article-24930.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Visceral metastasis at diagnosis<xref ref-type="bibr" rid="article-24930.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>BRAF mutation and NRAS mutation<xref ref-type="bibr" rid="article-24930.r4">[4]</xref><xref ref-type="bibr" rid="article-24930.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Activation of the phosphoinositide 3-kinase/protein kinase B pathway (PI3K/AKT)<xref ref-type="bibr" rid="article-24930.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Elevated LDH<xref ref-type="bibr" rid="article-24930.r2">[2]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24930.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence of melanoma is increasing worldwide and is the fifth leading cause of cancer in men and women in the United States.<xref ref-type="bibr" rid="article-24930.r7">[7]</xref>&#x000a0;Even though the incidence of melanoma is increasing, the mortality rates are beginning to decrease likely due to screening measures. Melanoma is rare in children and adolescents and the incidence continues to increase with age.<xref ref-type="bibr" rid="article-24930.r8">[8]</xref><xref ref-type="bibr" rid="article-24930.r9">[9]</xref>&#x000a0;Melanoma is more common in Whites than in Blacks or Asians.<xref ref-type="bibr" rid="article-24930.r10">[10]</xref></p>
        <p>Brain metastases (BM) is a common complication, especially with advanced-stage melanoma. Melanoma accounts for almost 10 percent of BM and the third leading cause after lung and breast cancer.<xref ref-type="bibr" rid="article-24930.r11">[11]</xref>&#x000a0;In a large multi-institutional adjuvant study, the incidence of BM is about 15 percent in Stage III melanoma, which predominantly occurred in the first 3 years after surgery.<xref ref-type="bibr" rid="article-24930.r12">[12]</xref>&#x000a0;The majority of the BM are supratentorial, with about 15 percent infratentorial.</p>
      </sec>
      <sec id="article-24930.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>BM has a highly variable clinical presentation. It should be suspected in a malignant melanoma patient with neurologic symptoms or behavioral abnormalities. The most common cause of the symptoms is due to the enlarging metastases and inflammatory edema surrounding the lesions in the brain. It is important to remember that the majority of patients initially can be asymptomatic.</p>
        <p>Headache is the most common presentation in BM and occurs in about 40% to 50% of patients.<xref ref-type="bibr" rid="article-24930.r13">[13]</xref> Associated symptoms of nausea, vomiting, abnormal neurologic exam, and positional change are suggestive of a possible BM. Focal neurologic symptoms are presenting symptoms in about 20-40 percent of the patients.<xref ref-type="bibr" rid="article-24930.r14">[14]</xref>&#x000a0;Cognitive dysfunction, stroke, seizures are other symptoms. BM in melanoma also has a higher propensity for spontaneously bleeding.</p>
      </sec>
      <sec id="article-24930.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>BM must be distinguished from primary brain tumors. Imaging studies are very useful to further evaluate the symptoms, but rarely some patients may need a definitive brain biopsy for diagnosis. Contrast-enhanced magnetic resonance imaging (MRI) is the preferred imaging modality for the diagnosis of BM. Non-contrasted MRI or CT scans are less sensitive compared to the contrast MRI.<xref ref-type="bibr" rid="article-24930.r15">[15]</xref><xref ref-type="bibr" rid="article-24930.r16">[16]</xref><xref ref-type="bibr" rid="article-24930.r17">[17]</xref>&#x000a0;</p>
        <p>Radiological features help differentiate BM from other CNS lesions. The following features are helpful to accurately characterize the BM</p>
        <list list-type="bullet">
          <list-item>
            <p>Presence of multiple lesions</p>
          </list-item>
          <list-item>
            <p>Tumor localization at the junction of the gray and white mater</p>
          </list-item>
          <list-item>
            <p>Large vasogenic edema compared with the size of the lesion</p>
          </list-item>
          <list-item>
            <p>Circumscribed margins</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24930.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The multidisciplinary approach is the cornerstone for the optimal management of patients with BM in melanoma and is strongly recommended by the National Comprehensive Cancer Network (NCCN). Conventional treatment for BM consists of the use of whole-brain radiation therapy (WBRT) for multiple metastatic lesions in the brain and stereotactic radiosurgery (SRS) for a limited number of lesions. Although CNS has been thought to be a sanctuary site for traditional systemic therapy options, recent data suggests it is not the case and systemic therapy modalities are being considered for disease control in the CNS.</p>
        <p>Advances in the neurosurgical techniques and stereotactic radiosurgery (SRS) along with systemic therapy options of immunotherapy and BRAF with MEK inhibitors have led to the major improvement in control of the BM and also improved the OS in these group of patients. SRS also has the ability to treat lesions that are not amenable for surgical resection.</p>
        <p>The key factors to consider in a patient with a new diagnosis of BM are:</p>
        <list list-type="order">
          <list-item>
            <p>The number, size, location, extent of CNS symptoms</p>
          </list-item>
          <list-item>
            <p>The extent of extracranial systemic disease</p>
          </list-item>
          <list-item>
            <p>BRAF mutation status</p>
          </list-item>
          <list-item>
            <p>Performance status of the patient and co-morbidities</p>
          </list-item>
          <list-item>
            <p>Prior systemic therapy</p>
          </list-item>
        </list>
        <p>Thus, the treatment is individualized depending on patient characteristics.</p>
        <p>Patients with new untreated BM and who are naive to systemic therapy, the initial therapy depends on the size of the lesions as well as if the patient is symptomatic. Patients with small, usually &#x0003c;1cm and minimally symptomatic or asymptomatic lesions, locoregional therapy (SRS or surgery) can be deferred and patients started on systemic therapy. A careful monitoring plan for intracranial progression is required. The choice of systemic therapy depends on if the melanoma harbors BRAF mutation. In BRAF &#x02013; mutant tumors, both the targeted therapy with BRAF with MEK inhibitors as well as immunotherapy combination nivolumab with ipilimumab is effective.<xref ref-type="bibr" rid="article-24930.r18">[18]</xref><xref ref-type="bibr" rid="article-24930.r19">[19]</xref>&#x000a0;In tumors that do not harbor the BRAF mutation, combination immunotherapy with nivolumab and ipilimumab is a reasonable option considering patients can tolerate the medications.<xref ref-type="bibr" rid="article-24930.r20">[20]</xref>&#x000a0;Rare patients with isolated BM SRS or surgery are still a reasonable front-line option.&#x000a0;</p>
        <p>For patients with large, symptomatic lesions, local control is a high priority, thus SRS or surgery is considered as front-line prior to systemic therapy. These patients also will need supportive measures like the use of high dose steroids, to control the edema. Patients who are not surgical candidates, RT alone, usually SRS or WBRT depending on the number of lesions is reasonable. For patients with new brain metastases but on current or prior systemic therapy, the options for systemic therapy are more limited, and thus local control is best achieved by SRS or surgery. Also, patients who are not eligible for systemic therapy with intracranial efficacy, locoregional therapy is offered.</p>
        <p>Imaging surveillance with brain MRI or contrast-enhanced CT of the head is critical for the follow-up of the brain metastases. The duration between scans depends on if loco-regional therapy was deferred or not. In patients who didn't receive loco-regional therapy, a scan every 8 to 12 weeks is recommended. In patients who received loco-regional therapy, a scan every 12 weeks is reasonable.</p>
      </sec>
      <sec id="article-24930.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>About 10% of mass lesions in the brain in patients with a history of cancer are not metastases. The differential diagnosis for a BM includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Abscess</p>
          </list-item>
          <list-item>
            <p>Acute demyelinating disorders</p>
          </list-item>
          <list-item>
            <p>Progressive multifocal leukoencephalopathy</p>
          </list-item>
          <list-item>
            <p>Radiation necrosis</p>
          </list-item>
          <list-item>
            <p>Granuloma</p>
          </list-item>
          <list-item>
            <p>Primary brain tumors like gliomas and astrocytoma</p>
          </list-item>
          <list-item>
            <p>Stroke</p>
          </list-item>
          <list-item>
            <p>Multiple sclerosis</p>
          </list-item>
          <list-item>
            <p>Nonbacterial thrombotic endocarditis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-24930.s9" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>Advances in neurosurgical techniques over the years have contributed to improvement in the management of the BM.<xref ref-type="bibr" rid="article-24930.r21">[21]</xref><xref ref-type="bibr" rid="article-24930.r22">[22]</xref><xref ref-type="bibr" rid="article-24930.r23">[23]</xref><xref ref-type="bibr" rid="article-24930.r24">[24]</xref>&#x000a0;Surgical resection is usually preferable for patients with a large lesion (usually &#x0003e; 3cm), solitary or very limited number of brain lesions, superficial lesions in areas where surgery do not lead to an unacceptable loss of function, posterior fossa metastatic lesions causing complications like brain herniation and with Karnofsky performance status 90 to 100 percent.<xref ref-type="bibr" rid="article-24930.r25">[25]</xref>&#x000a0;Post-surgical management usually involves SRS to the resection cavity to decrease the local recurrence. Even though no randomized controlled trials have been conducted, observational studies showed an increase in local control rates with SRS to the tumor bed.<xref ref-type="bibr" rid="article-24930.r26">[26]</xref><xref ref-type="bibr" rid="article-24930.r27">[27]</xref><xref ref-type="bibr" rid="article-24930.r28">[28]</xref></p>
      </sec>
      <sec id="article-24930.s10" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>SRS is gaining importance in the management of the BM in Melanoma. Compared to Whole Brain Radiotherapy (WBRT), SRS has better long-term safety and a decline in the neurocognitive function.<xref ref-type="bibr" rid="article-24930.r29">[29]</xref>&#x000a0;SRS may be administered by itself as a primary treatment to control the BM or as adjuvant therapy after surgical removal of the brain lesions as discussed above. WBRT is not recommended as adjuvant therapy.</p>
        <p>SRS is often given as a single fraction SRS or given over two &#x02013; five fractions. Usually, SRS is limited to patients with 3 -5 lesions, but recently some clinicians are using the SRS in patients with a higher number of lesions.<xref ref-type="bibr" rid="article-24930.r30">[30]</xref><xref ref-type="bibr" rid="article-24930.r31">[31]</xref>&#x000a0;On one study in patients with melanoma and BM, local control at 6 and 12 months was 87% and 68% respectively in patients treated with SRS.<xref ref-type="bibr" rid="article-24930.r32">[32]</xref></p>
      </sec>
      <sec id="article-24930.s11" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>Immunotherapy including ipilimumab, nivolumab, and pembrolizumab and targeted therapy with combination BRAF and MEK inhibitors are the first-line therapeutic options recommended for advanced melanoma. These groups of medications provided significant advances in the management of melanoma patients with untreated BM.</p>
        <p>
<bold>Immunotherapy</bold>
</p>
        <p>Since 2011, multiple immunotherapy medications were approved in patients with melanoma. Ipilimumab, a cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitor and programmed cell death-1(PD-1) inhibitors nivolumab, and pembrolizumab are currently approved in advanced melanoma.</p>
        <p>The combination of ipilimumab and nivolumab has an approximately 50% response rates in patients with asymptomatic BM.<xref ref-type="bibr" rid="article-24930.r20">[20]</xref>&#x000a0;CHECKMATE &#x02013; 204 is a phase II trial that enrolled melanoma patients with asymptomatic BM. Patients were given ipilimumab 3mg/kg every 3 weeks for 4 doses in combination with nivolumab 1 mg/kg. After the 4 doses, a maintenance nivolumab was given 3mg/kg every 2 weeks. The intracranial response rate was 55% with 29% complete response rates. The estimated OS at 18 months was 75%. ABC trial, another phase II trial similar to CHECKMATE -204, compared ipilimumab with nivolumab to single-agent nivolumab.<xref ref-type="bibr" rid="article-24930.r33">[33]</xref>&#x000a0;</p>
        <p>Combination therapy was noted to show a significantly higher intracranial response of 46% compared to 20% with single-agent nivolumab. A meta-analysis of patients with melanoma and BM showed the combination of ipilimumab and nivolumab was associated with improved PFS and OS.<xref ref-type="bibr" rid="article-24930.r18">[18]</xref>&#x000a0;Pembrolizumab as a single-agent demonstrated intracranial response rates of up to 26% and nivolumab up to 20% in patients with untreated BM in melanoma.<xref ref-type="bibr" rid="article-24930.r33">[33]</xref><xref ref-type="bibr" rid="article-24930.r34">[34]</xref><xref ref-type="bibr" rid="article-24930.r35">[35]</xref></p>
        <p>In symptomatic patients, there is limited data on the efficacy of immunotherapy as a sole initial therapy. Usually, these patients will require steroids with/without local CNS therapy before systemic therapy. It is recommended to decrease the dose of steroids to minimal or even discontinue them prior to the start of immunotherapy due to decreased efficacy of immunotherapy in combination with steroids.<xref ref-type="bibr" rid="article-24930.r36">[36]</xref></p>
        <p>
<bold>BRAF and MEK Inhibitors</bold>
</p>
        <p>Approximately 40% of melanomas harbor a BRAF mutation which is a component of the mitogen-activated protein kinase (MAPK) signaling pathway and activates the downstream MEK protein. By the use of molecularly targeted agents that inhibit the BRAF and MEK, the treatment of metastatic melanoma has improved significantly. The most common BRAF mutation is the V600E, but there are other mutations noted within the BRAF protein. Three combinations of BRAF plus MEK inhibitors are currently available which include dabrafenib plus trametinib, vemurafenib plus cobimetinib, and encorafenib plus binimetinib. To determine the efficacy of the combination of BRAF plus MEK inhibitors, a phase II COMBI-MB study evaluated dabrafenib and trametinib in multiple subsets of melanoma patients with BM. In the subset of patients with asymptomatic and no prior therapy to the BM with associated BRAF V600E mutation, intracranial response rates were about 60% with a median PFS of about 6 months.<xref ref-type="bibr" rid="article-24930.r19">[19]</xref>&#x000a0;</p>
        <p>Similar responses were also noted in other subsets of patients who received prior local therapy to the BM, harbor other BRAF mutations, and in symptomatic patients.<xref ref-type="bibr" rid="article-24930.r19">[19]</xref>&#x000a0;Due to radiation sensitization with BRAF inhibitors, it is recommended to hold the treatment with BRAF inhibitors with or without MEK inhibitors one to three days prior and one day after radiation therapy.<xref ref-type="bibr" rid="article-24930.r37">[37]</xref><xref ref-type="bibr" rid="article-24930.r38">[38]</xref><xref ref-type="bibr" rid="article-24930.r39">[39]</xref></p>
        <p>
<bold>Chemotherapy</bold>
</p>
        <p>Cytotoxic chemotherapy didn&#x02019;t show any efficacy in patients with BM alone or in combination with RT and has no significant role in the management of these patients.<xref ref-type="bibr" rid="article-24930.r40">[40]</xref><xref ref-type="bibr" rid="article-24930.r41">[41]</xref></p>
      </sec>
      <sec id="article-24930.s12" sec-type="Staging">
        <title>Staging</title>
        <p>Currently, the eighth edition of the American Joint Committee on Cancer (AJCC) tumor, node, metastasis (TNM) is used to stage Melanoma. This is based on the evaluation of the primary tumor, regional lymph nodes, lymphatic drainage, and distant metastases. A separate distant metastases (M) category was created in the eighth edition of the AJCC staging based upon the presence of CNS metastases. Patients with CNS metastases with or without the involvement of the other sites are staged as M1d.<xref ref-type="bibr" rid="article-24930.r42">[42]</xref></p>
      </sec>
      <sec id="article-24930.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Melanoma patients with BM historically had a dismal prognosis. Before 2000, the median survival was 3 to 4 months with one-year survival &#x0003c;10%.<xref ref-type="bibr" rid="article-24930.r43">[43]</xref><xref ref-type="bibr" rid="article-24930.r44">[44]</xref><xref ref-type="bibr" rid="article-24930.r45">[45]</xref>&#x000a0;Significant advances made in the last two decades with radiation therapy in BM as well as systemic therapy in melanoma has significantly improved the prognosis. One study enrolled 179 patients with BM secondary to melanoma who are subsequently treated with SRS and systemic therapy involving immunotherapy or targeted therapy. The one year and two-year OS were 50% and 27% respectively.<xref ref-type="bibr" rid="article-24930.r46">[46]</xref>&#x000a0;A variety of tools were developed for prognostication in individual melanoma patients. These include the Basic Score for Brain Metastases (BSBM), score index or radiosurgery in BM, and a diagnosis-specific graded prognostic assessment tool for patients with melanoma brain metastases.<xref ref-type="bibr" rid="article-24930.r47">[47]</xref><xref ref-type="bibr" rid="article-24930.r48">[48]</xref><xref ref-type="bibr" rid="article-24930.r49">[49]</xref><xref ref-type="bibr" rid="article-24930.r50">[50]</xref></p>
      </sec>
      <sec id="article-24930.s14" sec-type="Complications">
        <title>Complications</title>
        <p>Seizures, stroke, cognitive dysfunction, hemorrhage into the brain, obstructive hydrocephalus, spinal cord compression, and death are some of the complications related to the metastasis to the CNS.</p>
      </sec>
      <sec id="article-24930.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education is paramount to the appropriate management of malignant melanoma prevention as well as after diagnosis. Skin cancer preventative education for patients as well as their families is important. Proper precautions, as well as regular sunscreen use, may diminish the incidence of subsequent melanoma. The diagnosis of metastasis to the CNS in melanoma patients is a difficult discussion and constitutes the incurable nature of the disease.</p>
        <p>Education should be given regarding the multi-disciplinary care and involvement of surgical oncology, radiation oncology, and medical oncology along with other allied health professionals. Educating patients regarding the goals of treatment, available treatment options, side effects associated with the various treatments help them choose their care according to their goals and beliefs with emphasis on compliance with follow up visits and surveillance scans. Education and resources regarding the end of life care should be provided to the patients and their families.</p>
      </sec>
      <sec id="article-24930.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Management of metastatic melanoma to the CNS is complex and needs a multidisciplinary team approach involving surgical oncologists, neurosurgeons, medical oncologists, radiation oncologists, dermatology, pathologists, and radiologists. It is recommended these complex patients discussed in a multidisciplinary tumor board for a consensus treatment plan. This approach will facilitate optimal patient care, individualized treatment decisions, and also improve enrollment in the clinical trials. Medical oncology and radiation oncology play a critical role in the management of CNS metastases. Appropriate histopathologic diagnosis with associated harboring mutations helps direct targeted therapies to control the disease/ Medical oncologists make treatment decisions and oversee the administration of systemic medications like immunotherapy and targeted therapies.</p>
        <p>Radiation oncologists use WBRT or SRS to help manage the symptoms as well as control the growth of the BM. Oncologic pharmacists review medications, verify doses and play a very important role in the administration and side effect management. Oncology nurses staff the infusion center to administer the systemic medications and closely monitor for any associated side effects. The decision&#x000a0;on when to stop treating a patient with CNS metastases as well as metastatic melanoma can be difficult, and this decision should involve the patient, family, friends, and the healthcare team. Extensive communication of interdisciplinary teams with the patient and families improve the outcomes of patients with metastatic melanoma to the CNS.<xref ref-type="bibr" rid="article-24930.r51">[51]</xref><xref ref-type="bibr" rid="article-24930.r52">[52]</xref><xref ref-type="bibr" rid="article-24930.r53">[53]</xref></p>
      </sec>
      <sec id="article-24930.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=24930&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=24930">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/malignant-melanoma-metastatic-to-the-central-nervous-system/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=24930">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/24930/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=24930">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-24930.s18">
        <title>References</title>
        <ref id="article-24930.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balch</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Soong</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Gershenwald</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Reintgen</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Cascinelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Urist</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McMasters</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Kirkwood</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Coit</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Desmond</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Lyman</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Morabito</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.</article-title>
            <source>J Clin Oncol</source>
            <year>2001</year>
            <month>Aug</month>
            <day>15</day>
            <volume>19</volume>
            <issue>16</issue>
            <fpage>3622</fpage>
            <page-range>3622-34</page-range>
            <pub-id pub-id-type="pmid">11504744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bedikian</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Detry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Hwu</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Homsi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hwu</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma.</article-title>
            <source>Am J Clin Oncol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>603</fpage>
            <page-range>603-10</page-range>
            <pub-id pub-id-type="pmid">21150567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ballo</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Cormier</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Gershenwald</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Hwu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zagars</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Combined-modality therapy for patients with regional nodal metastases from melanoma.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2006</year>
            <month>Jan</month>
            <day>01</day>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>106</fpage>
            <page-range>106-13</page-range>
            <pub-id pub-id-type="pmid">16182463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kotecha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Venur</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Mohammadi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Funchain</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Vogelbaum</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Angelov</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ahluwalia</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.</article-title>
            <source>J Neurosurg</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>129</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-59</page-range>
            <pub-id pub-id-type="pmid">28799876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thumar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shahbazian</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Aziz</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Jilaveanu</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>MEK targeting in N-RAS mutated metastatic melanoma.</article-title>
            <source>Mol Cancer</source>
            <year>2014</year>
            <month>Mar</month>
            <day>04</day>
            <volume>13</volume>
            <fpage>45</fpage>
            <pub-id pub-id-type="pmid">24588908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chakravarti</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aardalen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Tetzlaff</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Wubbenhorst</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Kopetz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ledoux</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Gopal</surname>
                <given-names>YN</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Nathanson</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Aldape</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Prieto</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Stuart</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target.</article-title>
            <source>Clin Cancer Res</source>
            <year>2014</year>
            <month>Nov</month>
            <day>01</day>
            <volume>20</volume>
            <issue>21</issue>
            <fpage>5537</fpage>
            <page-range>5537-46</page-range>
            <pub-id pub-id-type="pmid">24803579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cancer statistics, 2019.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-34</page-range>
            <pub-id pub-id-type="pmid">30620402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lange</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Palis</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Soong</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Balch</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base.</article-title>
            <source>J Clin Oncol</source>
            <year>2007</year>
            <month>Apr</month>
            <day>10</day>
            <volume>25</volume>
            <issue>11</issue>
            <fpage>1363</fpage>
            <page-range>1363-8</page-range>
            <pub-id pub-id-type="pmid">17416855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strouse</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Fears</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Tucker</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wayne</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Jul</month>
            <day>20</day>
            <volume>23</volume>
            <issue>21</issue>
            <fpage>4735</fpage>
            <page-range>4735-41</page-range>
            <pub-id pub-id-type="pmid">16034049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paulson</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Veatch</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wojcik</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chapuis</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Madeleine</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Age-Specific Incidence of Melanoma in the United States.</article-title>
            <source>JAMA Dermatol</source>
            <year>2020</year>
            <month>Jan</month>
            <day>01</day>
            <volume>156</volume>
            <issue>1</issue>
            <fpage>57</fpage>
            <page-range>57-64</page-range>
            <pub-id pub-id-type="pmid">31721989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Demographics of brain metastasis.</article-title>
            <source>Neurosurg Clin N Am</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>337</fpage>
            <page-range>337-44</page-range>
            <pub-id pub-id-type="pmid">8823767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samlowski</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Witter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Kirkwood</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Othus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ribas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sondak</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Flaherty</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>High frequency of brain metastases after adjuvant therapy for high-risk melanoma.</article-title>
            <source>Cancer Med</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>11</issue>
            <fpage>2576</fpage>
            <page-range>2576-2585</page-range>
            <pub-id pub-id-type="pmid">28994212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forsyth</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Posner</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Headaches in patients with brain tumors: a study of 111 patients.</article-title>
            <source>Neurology</source>
            <year>1993</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>9</issue>
            <fpage>1678</fpage>
            <page-range>1678-83</page-range>
            <pub-id pub-id-type="pmid">8414011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clouston</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Posner</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>The spectrum of neurological disease in patients with systemic cancer.</article-title>
            <source>Ann Neurol</source>
            <year>1992</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>268</fpage>
            <page-range>268-73</page-range>
            <pub-id pub-id-type="pmid">1637135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sze</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heier</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>1990</year>
            <season>Jul-Aug</season>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>785</fpage>
            <page-range>785-91</page-range>
            <pub-id pub-id-type="pmid">2114769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davis</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Hudgins</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Peterman</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>1991</year>
            <season>Mar-Apr</season>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>293</fpage>
            <page-range>293-300</page-range>
            <pub-id pub-id-type="pmid">1902031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schaefer</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Budzik</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Imaging of cerebral metastases.</article-title>
            <source>Neurosurg Clin N Am</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>393</fpage>
            <page-range>393-423</page-range>
            <pub-id pub-id-type="pmid">8823771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rulli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Legramandi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Salvati</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mandala</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis.</article-title>
            <source>Cancer</source>
            <year>2019</year>
            <month>Nov</month>
            <day>01</day>
            <volume>125</volume>
            <issue>21</issue>
            <fpage>3776</fpage>
            <page-range>3776-3789</page-range>
            <pub-id pub-id-type="pmid">31287564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Saiag</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grob</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Flaherty</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Arance</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chiarion-Sileni</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lesimple</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mortier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moschos</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hogg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>M&#x000e1;rquez-Rodas</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Del Vecchio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lebb&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mookerjee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>GV</given-names>
              </name>
            </person-group>
            <article-title>Dabrafenib plus trametinib in patients with BRAF<sup>V600</sup>-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>7</issue>
            <fpage>863</fpage>
            <page-range>863-873</page-range>
            <pub-id pub-id-type="pmid">28592387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tawbi</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Forsyth</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Algazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamid</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hodi</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Moschos</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Khushalani</surname>
                <given-names>NI</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lao</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Postow</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Ernstoff</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Reardon</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Puzanov</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kudchadkar</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Tarhini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pavlick</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Avila</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Demelo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Margolin</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Aug</month>
            <day>23</day>
            <volume>379</volume>
            <issue>8</issue>
            <fpage>722</fpage>
            <page-range>722-730</page-range>
            <pub-id pub-id-type="pmid">30134131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonald</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Lewine</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Burr</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Koehler</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Tsuruda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Orrison</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Heilbrun</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Integration of preoperative and intraoperative functional brain mapping in a frameless stereotactic environment for lesions near eloquent cortex. Technical note.</article-title>
            <source>J Neurosurg</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>90</volume>
            <issue>3</issue>
            <fpage>591</fpage>
            <page-range>591-8</page-range>
            <pub-id pub-id-type="pmid">10067937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lunsford</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Subach</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Jho</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Bissonette</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kondziolka</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Brain surgery with image guidance: current recommendations based on a 20-year assessment.</article-title>
            <source>Stereotact Funct Neurosurg</source>
            <year>2000</year>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-48</page-range>
            <pub-id pub-id-type="pmid">11416263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hatiboglu</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Suki</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sawaya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wildrick</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Weinberg</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Outcomes and prognostic factors for patients with brainstem metastases undergoing stereotactic radiosurgery.</article-title>
            <source>Neurosurgery</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>69</volume>
            <issue>4</issue>
            <fpage>796</fpage>
            <page-range>796-806; discussion 806</page-range>
            <pub-id pub-id-type="pmid">21508879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sills</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Current treatment approaches to surgery for brain metastases.</article-title>
            <source>Neurosurgery</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>57</volume>
            <issue>5 Suppl</issue>
            <fpage>S24</fpage>
            <page-range>S24-32; discusssion S1-4</page-range>
            <pub-id pub-id-type="pmid">16237284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paek</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Audu</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques.</article-title>
            <source>Neurosurgery</source>
            <year>2005</year>
            <month>May</month>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>1021</fpage>
            <page-range>1021-34; discussion 1021-34</page-range>
            <pub-id pub-id-type="pmid">15854250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Ballman</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Cerhan</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Carrero</surname>
                <given-names>XW</given-names>
              </name>
              <name>
                <surname>Whitton</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Greenspoon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Parney</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Laack</surname>
                <given-names>NNI</given-names>
              </name>
              <name>
                <surname>Ashman</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Bahary</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hadjipanayis</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Urbanic</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Farace</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Khuntia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Giannini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Buckner</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Galanis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roberge</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC&#x000b7;3): a multicentre, randomised, controlled, phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>1049</fpage>
            <page-range>1049-1060</page-range>
            <pub-id pub-id-type="pmid">28687377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahajan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McAleer</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Weinberg</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Settle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prabhu</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>McGovern</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sulman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McCutcheon</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Azeem</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cahill</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tatsui</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heimberger</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ghia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Demonte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Raza</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guha-Thakurta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sawaya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>1040</fpage>
            <page-range>1040-1048</page-range>
            <pub-id pub-id-type="pmid">28687375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Harsh</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Lieberson</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Soltys</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2012</year>
            <month>Oct</month>
            <day>01</day>
            <volume>84</volume>
            <issue>2</issue>
            <fpage>336</fpage>
            <page-range>336-42</page-range>
            <pub-id pub-id-type="pmid">22652105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Jaeckle</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ballman</surname>
                <given-names>KV</given-names>
              </name>
              <name>
                <surname>Farace</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cerhan</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Carrero</surname>
                <given-names>XW</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Deming</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Burri</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>M&#x000e9;nard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stieber</surname>
                <given-names>VW</given-names>
              </name>
              <name>
                <surname>Pollock</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Galanis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Buckner</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Asher</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Jul</month>
            <day>26</day>
            <volume>316</volume>
            <issue>4</issue>
            <fpage>401</fpage>
            <page-range>401-409</page-range>
            <pub-id pub-id-type="pmid">27458945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salvetti</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Nagaraja</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>McNeill</surname>
                <given-names>IT</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sheehan</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Gamma Knife surgery for the treatment of 5 to 15 metastases to the brain: clinical article.</article-title>
            <source>J Neurosurg</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>118</volume>
            <issue>6</issue>
            <fpage>1250</fpage>
            <page-range>1250-7</page-range>
            <pub-id pub-id-type="pmid">23540265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rava</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leonard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sioshansi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Curran</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wazer</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Cosgrove</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Nor&#x000e9;n</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hepel</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Survival among patients with 10 or more brain metastases treated with stereotactic radiosurgery.</article-title>
            <source>J Neurosurg</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>119</volume>
            <issue>2</issue>
            <fpage>457</fpage>
            <page-range>457-62</page-range>
            <pub-id pub-id-type="pmid">23662828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernard</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Wegner</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Reineman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Heron</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Kirkwood</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Burton</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Mintz</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Linear accelerator based stereotactic radiosurgery for melanoma brain metastases.</article-title>
            <source>J Cancer Res Ther</source>
            <year>2012</year>
            <season>Apr-Jun</season>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>215</fpage>
            <page-range>215-21</page-range>
            <pub-id pub-id-type="pmid">22842364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Long</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guminski</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Wilmott</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scolyer</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.</article-title>
            <source>Lancet Oncol</source>
            <year>2018</year>
            <month>May</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>672</fpage>
            <page-range>672-681</page-range>
            <pub-id pub-id-type="pmid">29602646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kluger</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zito</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Sznol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hegde</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Perrotti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ralabate</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Jilaveanu</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.</article-title>
            <source>J Clin Oncol</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <page-range>52-60</page-range>
            <pub-id pub-id-type="pmid">30407895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldberg</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Gettinger</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Herbst</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Sznol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsiouris</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vortmeyer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jilaveanu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hegde</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Speaker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Madura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ralabate</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rivera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rowen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gerrish</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>17</volume>
            <issue>7</issue>
            <fpage>976</fpage>
            <page-range>976-983</page-range>
            <pub-id pub-id-type="pmid">27267608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Della Corte</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Morgillo</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Early use of steroids affects immune cells and impairs immunotherapy efficacy.</article-title>
            <source>ESMO Open</source>
            <year>2019</year>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>e000477</fpage>
            <pub-id pub-id-type="pmid">30964127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anker</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Grossmann</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Suneja</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tarhini</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kirkwood</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2016</year>
            <month>Jun</month>
            <day>01</day>
            <volume>95</volume>
            <issue>2</issue>
            <fpage>632</fpage>
            <page-range>632-46</page-range>
            <pub-id pub-id-type="pmid">27131079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merten</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hecht</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haderlein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Distel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fietkau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heinzerling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Semrau</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy.</article-title>
            <source>Strahlenther Onkol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>190</volume>
            <issue>12</issue>
            <fpage>1169</fpage>
            <page-range>1169-72</page-range>
            <pub-id pub-id-type="pmid">24965480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boussemart</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boivin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Claveau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>YG</given-names>
              </name>
              <name>
                <surname>Tomasic</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Routier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mateus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Deutsch</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Vemurafenib and radiosensitization.</article-title>
            <source>JAMA Dermatol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>149</volume>
            <issue>7</issue>
            <fpage>855</fpage>
            <page-range>855-7</page-range>
            <pub-id pub-id-type="pmid">23699661</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Margolin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ernstoff</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Flaherty</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sosman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>II Smith</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dutcher</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gollob</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Longmate</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group.</article-title>
            <source>J Cancer Res Clin Oncol</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>128</volume>
            <issue>4</issue>
            <fpage>214</fpage>
            <page-range>214-8</page-range>
            <pub-id pub-id-type="pmid">11935312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacquillat</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Khayat</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Banzet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Weil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fumoleau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Avril</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Namer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bonneterre</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kerbrat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bonerandi</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.</article-title>
            <source>Cancer</source>
            <year>1990</year>
            <month>Nov</month>
            <day>01</day>
            <volume>66</volume>
            <issue>9</issue>
            <fpage>1873</fpage>
            <page-range>1873-8</page-range>
            <pub-id pub-id-type="pmid">2224783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gershenwald</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Scolyer</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Correction to: Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond.</article-title>
            <source>Ann Surg Oncol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>Suppl 3</issue>
            <fpage>993</fpage>
            <page-range>993-994</page-range>
            <pub-id pub-id-type="pmid">30105437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sampson</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Seigler</surname>
                <given-names>HF</given-names>
              </name>
            </person-group>
            <article-title>Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.</article-title>
            <source>J Neurosurg</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-20</page-range>
            <pub-id pub-id-type="pmid">9420067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fife</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Colman</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Firth</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shannon</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Harman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Petersen-Schaefer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zacest</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Besser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Milton</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Determinants of outcome in melanoma patients with cerebral metastases.</article-title>
            <source>J Clin Oncol</source>
            <year>2004</year>
            <month>Apr</month>
            <day>01</day>
            <volume>22</volume>
            <issue>7</issue>
            <fpage>1293</fpage>
            <page-range>1293-300</page-range>
            <pub-id pub-id-type="pmid">15051777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hwu</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Hwu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bedikian</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors for survival in melanoma patients with brain metastases.</article-title>
            <source>Cancer</source>
            <year>2011</year>
            <month>Apr</month>
            <day>15</day>
            <volume>117</volume>
            <issue>8</issue>
            <fpage>1687</fpage>
            <page-range>1687-96</page-range>
            <pub-id pub-id-type="pmid">20960525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaudy-Marqueste</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dussouil</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Carron</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Troin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Malissen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Loundou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Monestier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mallet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>R&#x000e9;gis</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Grob</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery.</article-title>
            <source>Eur J Cancer</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>84</volume>
            <fpage>44</fpage>
            <page-range>44-54</page-range>
            <pub-id pub-id-type="pmid">28783540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buchsbaum</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Chidel</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Greskovich</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study.</article-title>
            <source>Cancer</source>
            <year>2002</year>
            <month>Apr</month>
            <day>15</day>
            <volume>94</volume>
            <issue>8</issue>
            <fpage>2265</fpage>
            <page-range>2265-72</page-range>
            <pub-id pub-id-type="pmid">12001126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sperduto</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Kased</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Roberge</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shanley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Sneed</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Weil</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Kirkpatrick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gaspar</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Fiveash</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Knisely</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Sperduto</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases.</article-title>
            <source>J Clin Oncol</source>
            <year>2012</year>
            <month>Feb</month>
            <day>01</day>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>419</fpage>
            <page-range>419-25</page-range>
            <pub-id pub-id-type="pmid">22203767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Serizawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Higuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nagano</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ono</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saeki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hirai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Miyakawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shibamoto</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>A new grading system focusing on neurological outcomes for brain metastases treated with stereotactic radiosurgery: the modified Basic Score for Brain Metastases.</article-title>
            <source>J Neurosurg</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>121 Suppl</volume>
            <fpage>35</fpage>
            <page-range>35-43</page-range>
            <pub-id pub-id-type="pmid">25434935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lorenzoni</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Devriendt</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Massager</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Desmedt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van Houtte</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brotchi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levivier</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Brain stem metastases treated with radiosurgery: prognostic factors of survival and life expectancy estimation.</article-title>
            <source>Surg Neurol</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>71</volume>
            <issue>2</issue>
            <fpage>188</fpage>
            <page-range>188-95; discussion 195, 195-6</page-range>
            <pub-id pub-id-type="pmid">18439658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marsden</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Newton-Bishop</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Burrows</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Corrie</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Gore</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Lorigan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mackie</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Peach</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Powell</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>C</given-names>
              </name>
              <collab>British Association of Dermatologists (BAD) Clinical Standards Unit</collab>
            </person-group>
            <article-title>Revised UK guidelines for the management of cutaneous melanoma 2010.</article-title>
            <source>J Plast Reconstr Aesthet Surg</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>63</volume>
            <issue>9</issue>
            <fpage>1401</fpage>
            <page-range>1401-19</page-range>
            <pub-id pub-id-type="pmid">20728418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kesson</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Allardice</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women.</article-title>
            <source>BMJ</source>
            <year>2012</year>
            <month>Apr</month>
            <day>26</day>
            <volume>344</volume>
            <fpage>e2718</fpage>
            <pub-id pub-id-type="pmid">22539013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-24930.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hauschild</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lindenblatt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pentheroudakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Keilholz</surname>
                <given-names>U</given-names>
              </name>
              <collab>ESMO Guidelines Committee</collab>
            </person-group>
            <article-title>Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</article-title>
            <source>Ann Oncol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>26 Suppl 5</volume>
            <fpage>v126</fpage>
            <page-range>v126-32</page-range>
            <pub-id pub-id-type="pmid">26314774</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
